STOCK TITAN

Astrazeneca plc - AZN STOCK NEWS

Welcome to our dedicated news page for Astrazeneca plc (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on Astrazeneca plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Astrazeneca plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Astrazeneca plc's position in the market.

Rhea-AI Summary
Positive results from the MANDARA Phase III trial for FASENRA in patients with EGPA were published, showing that FASENRA enabled patients to taper off oral corticosteroids while preventing relapses. The trial demonstrated that more than half of patients achieved remission with eosinophil-targeting biologic therapies, with benralizumab meeting the primary endpoint and showing non-inferior rates of remission compared to mepolizumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
clinical trial
-
Rhea-AI Summary
AstraZeneca's TAGRISSO shows significant progression-free survival benefit in Stage III lung cancer patients with EGFR mutations, positioning it as a potential targeted treatment option. The LAURA Phase III trial results indicate a favorable trend in overall survival, with TAGRISSO demonstrating impactful clinical benefit in a potentially curative setting. Safety and tolerability profiles remain consistent, with ongoing investigations in neoadjuvant and adjuvant settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's Biologics License Application for datopotamab deruxtecan has been accepted in the U.S. for the treatment of nonsquamous non-small cell lung cancer. The application is based on results from the TROPION-Lung01 phase 3 trial, showing significant improvements in progression-free survival compared to standard care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
AstraZeneca's TAGRISSO with chemotherapy has been approved in the US for EGFRm NSCLC treatment based on FLAURA2 results, showing significant PFS improvement. The addition of chemotherapy reduced the risk of disease progression by 38% compared to monotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
AstraZeneca reports strong financial performance for FY 2023 with a 6% increase in total revenue, driven by double-digit growth in oncology, CVRM, R&I, and rare disease. Core EPS increased by 15% to $7.26, and a second interim dividend of $1.97 per share was declared. The company expects a low double-digit to low teens percentage increase in total revenue and core EPS for FY 2024. Key milestones include three new molecular entities approved and multiple international approvals for various medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
earnings
-
Rhea-AI Summary
SOPHiA GENETICS and AstraZeneca Spain have expanded their HRD testing program in Spain to support the molecular diagnosis of ovarian cancer. The program aims to increase access to local testing for homologous recombination deficiency (HRD) throughout the country, with the goal of making vital testing available to thousands more patients. AstraZeneca Spain has named SOPHiA GENETICS its preferred partner in deploying HRD testing throughout Spain, offering the option for HRD testing to become available to more laboratories. The collaboration aims to increase accelerated diagnostics for patients and support clinicians in precision treatment planning.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
Rhea-AI Summary
SOPHiA GENETICS and AstraZeneca Spain have expanded their HRD testing program in Spain to support the molecular diagnosis of ovarian cancer. The program aims to increase access to local testing for homologous recombination deficiency (HRD) throughout the country, with the goal of making vital testing available to thousands more patients. AstraZeneca Spain has named SOPHiA GENETICS its preferred partner in deploying HRD testing throughout Spain, offering the option for HRD testing to become available to more laboratories. The collaboration aims to increase accelerated diagnostics for patients and support clinicians in precision treatment planning.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
AstraZeneca invests $300 million in a new facility in Rockville, MD to launch life-saving cell therapy platforms for cancer trials and future commercial supply, creating over 150 highly skilled jobs. The facility will focus on manufacturing T-cell therapies for clinical trials and may expand to support other disease areas. This investment aims to make next-generation cell therapy a reality, accelerating the company's ambition to meet patient demands. The facility will be located near the company's R&D center and within the booming life sciences corridor in Maryland, providing an attractive environment for talent recruitment. AstraZeneca is building a cell therapy portfolio to empower T-cells to fight cancer more effectively, including CAR-Ts targeting solid tumors and a pipeline of novel T-cell receptor therapies through Neogene Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.92%
Tags
none
-
Rhea-AI Summary
AstraZeneca and Daiichi Sankyo's ENHERTU granted Priority Review by the FDA for the treatment of HER2-positive solid tumors based on promising clinical trial data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
none
Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's ENHERTU has been granted Priority Review in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive solid tumors. The Prescription Drug User Fee Act (PDUFA) date is May 30, 2024. The sBLA is being reviewed under the Real-Time Oncology Review (RTOR) program and Project Orbis. The application is based on results from the DESTINY-PanTumor02 trial and supported by additional ENHERTU data. If approved, ENHERTU will potentially be the first HER2 directed treatment and antibody drug conjugate to receive a tumor agnostic indication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
none
Astrazeneca plc

Nasdaq:AZN

AZN Rankings

AZN Stock Data

201.48B
1.55B
0.01%
16.8%
0.29%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Cambridge

About AZN

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.